Laroprovstat

also known as AZD0780

Small molecule targets PCSK9 via inhibition

Developed for: hyperlipidemia · cardiovascular disorder · atherosclerotic cardiovascular disease · familial hypercholesterolemia
Investigated by: AstraZeneca · Parexel · Fortrea · Quotient Sciences

Trials 18

today NCT07622433 · Ph 1 NCT07513571 · Ph 1 NCT07316608 · Ph 1 NCT07423598 · Ph 1 NCT07218900 · Ph 2 NCT07216131 · Ph 1 NCT07000136 · Ph 3 NCT07000357 · Ph 3 NCT07000123 · Ph 3 NCT06742853 · Ph 1 NCT06834932 · Ph 2/3 NCT06692764 · Ph 2 NCT06671405 · Ph 1 NCT06576765 · Ph 1 NCT06592482 · Ph 1 NCT06173570 · Ph 2 NCT05817461 · Ph 1 NCT05787002 · Ph 1

20232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 111 trials
Phase 1	NCT07622433	Jun → Sep 2026	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT07513571	Apr → Jul 2026 overdue	—	AstraZeneca	Recruiting	No outcome recorded
Phase 1	NCT07316608	Mar → Jun 2026	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT07423598	Feb → Jun 2026	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT07216131	Nov → Dec 2025	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06742853	Dec 2024 → Oct 2025	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06671405	Sep 2024 → Feb 2025	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06576765	Aug → Nov 2024	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06592482	Aug → Dec 2024	impaired renal function disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT05817461	Apr → Jun 2023	cardiovascular disorder	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT05787002	Mar → May 2023	hyperlipidemia	AstraZeneca	Completed	No outcome recorded

Phase 23 trials · 1 met primary
Phase 2	NCT07218900	Nov 2025 → Sep 2026 overdue	hyperlipidemia	AstraZeneca	Active not recruiting	No outcome recorded
Phase 2	NCT06692764	Oct 2024 → Apr 2025	atherosclerotic cardiovascular disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT06173570	Jan → Sep 2024	hyperlipidemia	AstraZeneca	Completed	Met primary
Phase 2/31 trial
Phase 2/3	NCT06834932	Dec 2024 → Feb 2027 expected	hyperlipidemia	AstraZeneca	Active not recruiting	No outcome recorded
Phase 33 trials
Phase 3	NCT07000136	Jun 2025 → Jan 2027 expected	familial hypercholesterolemia	AstraZeneca	Active not recruiting	No outcome recorded
Phase 3	NCT07000357	Jun 2025 → Oct 2029 expected	cardiovascular disorder	AstraZeneca	Recruiting	No outcome recorded
Phase 3	NCT07000123	May 2025 → Jan 2027 expected	cardiovascular disorder	AstraZeneca	Active not recruiting	No outcome recorded
Comparator or background therapy3 trials
Phase 1	NCT05384262 Comparator	May 2022 → Jun 2024	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT07619118 Comparator	Sep 2026 → May 2027 expected	hyperlipidemia	AstraZeneca	Recruiting	No outcome recorded
Phase 3	NCT07619131 Comparator	Aug 2026 → Jul 2027 expected	hyperlipidemia	AstraZeneca	Recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2025-03-31	AstraZeneca	Results AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial astrazeneca.com ↗ Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.

All press releases naming this drug 1 release

Date	Issuer	Release
2025-03-31	AstraZeneca	AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial astrazeneca.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 22 sources stand behind the page.

Field	Value	Cited text
Known as	Laroprovstat	“METHODS: Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design that binds to the PCSK9 C-terminal domain.” PMID 42137960 ↗ May 2026 5 NCT07619118 ↗ NCT07513571 ↗ NCT07619131 ↗ NCT07622433 ↗ NCT07316608 ↗
Known as	AZD0780	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07216131 ↗ 15 NCT06834932 ↗ NCT06576765 ↗ NCT05787002 ↗ NCT06692764 ↗ NCT07000357 ↗ NCT07000136 ↗ NCT06173570 ↗ NCT07000123 ↗ NCT07218900 ↗ NCT06671405 ↗ Show 5 more sources
Action	Inhibit	“Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia” PMID 42137960 ↗ May 2026
Modality	Small molecule	“Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design” PMID 42137960 ↗ May 2026
Route	Oral	“Subjects will receive AZD0780 orally as a multiple ascending dose.” NCT05384262 ↗
Target	PCSK9	“binds to the PCSK9 C-terminal domain” PMID 42137960 ↗ May 2026